# OnCo record nexavar-compulsory-licence (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/nexavar-compulsory-licence/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "nexavar-compulsory-licence" ;
  schema:name "Nexavar compulsory licence (India, 2012)"@en ;
  schema:alternateName "Nexavar compulsory license"@en, "Natco v Bayer"@en, "Natco Pharma v Bayer"@en, "India compulsory licence"@en, "compulsory licence"@en, "compulsory license"@en, "compulsory licensing"@en, "section 84 Patents Act"@en ;
  schema:description "In March 2012 India's patent office let Natco make a generic of Bayer's kidney and liver cancer drug sorafenib at about 3 percent of the branded price, paying a royalty, because Bayer had priced it beyond most Indians' reach; it remains the leading example of a compulsory licence on a cancer drug."@en ;
  schema:url <https://onco.cc/terms/nexavar-compulsory-licence/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Compulsory_license> ;
  schema:citation <https://en.wikipedia.org/wiki/Compulsory_license>, <https://en.wikipedia.org/wiki/Sorafenib> ;
  onco:tag "law", "in" ;
  onco:related <https://onco.cc/terms/trips-doha/>, <https://onco.cc/terms/novartis-glivec-ruling/>, <https://onco.cc/terms/india-new-drugs-rules-2019/>, <https://onco.cc/terms/hatch-waxman/>, <https://onco.cc/terms/us-regulatory-exclusivity/>, <https://onco.cc/terms/drug-price-transparency/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/terms/who-essential-medicines/>, <https://onco.cc/terms/myriad-ruling/> ;
  onco:drugs <https://onco.cc/drugs/sorafenib/> ;
  onco:companies <https://onco.cc/companies/natco/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/cipla/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-ip-collaboration/> .